Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Journal
Infection
Date Issued
2023-01-17
Author(s)
Johnson, Matthew G
Strizki, Julie M
Brown, Michelle L
Wan, Hong
Shamsuddin, Hala H
Ramgopal, Moti
Florescu, Diana F
Delobel, Pierre
Khaertynova, Ilsiyar
Flores, José F
Fouche, Leon F
Williams-Diaz, Angela
Du, Jiejun
Grobler, Jay A
Paschke, Amanda
De Anda, Carisa
Abstract
Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial.
Subjects
COVID-19; Immunocompromised; Molnupiravir; Treatment; Virology
Type
journal article